Strategic Communication and Public Relations

DKTK Berlin: Boost for cancer therapies with tumors grown in petri-dish

2.6 Million Euros for the Charité

No. 45 | 04/11/2016 | by AM

Cancer can be caused by a variety of genetic mutations. One challenge medicine faces is finding tailor-made treatment for each patient based on their individual genetic differences. Scientists at the German Cancer Consortium (DKTK) at the Charité Comprehensive Cancer Center in Berlin have now received 2.6 million Euros so, together with regional biotechnology companies, they can make test systems available for personalized medication screening. The German Cancer Consortium (DKTK) builds a strong, long-term, institutional structure between the German Cancer Research Center (DKFZ) and universities and university hospitals all over Germany specially designated to clinical oriented cancer research.

Colon cancer cells growing into a 3-dimensional organoid cell culture in a culture dish.
© Dr. Joseph Regan

Scientists are constantly developing new drugs designed to specifically target the mutated cells. However, despite a very similar diagnosis and symptoms, patients' reactions to the same therapies vary substantially. This is because the genetic makeup of individual tumors differs. The grant they are now to receive from the European Fund for Regional development (EFRE) enables the Charité to launch a cooperation project with three regional biotech companies. The project is called Precision Oncology and Personalized Therapy Prediction, or POP for short. Its goal is to further develop test systems for medication screening, which reflect the varied tumor characteristics of individual patients.

Patient-specific cell cultures and mouse models enabling scientists to assess and evaluate the effectiveness of a drug in advance are considered the new hope in personalized drug therapy. Three-dimensional cell cultures enable scientists to simulate the tissue structure and the cell metabolism in tumor cell groups, in order to test dosage and the effectiveness of drug candidates as realistically as possible.

"The first step is to screen protein pools and genetic profiles of our patients' tumors for a pattern of tumor-specific mutations" explains Prof Ulrich Keilholz, director of the Charité Comprehensive Cancer Center (CCCC) and head of the project. "As a clinical partner of the DKTK, we have access to databases of extensively characterized tumor profiles, and state of the art high-throughput analytical techniques helping us to define new targets for future medicines." The scientists then cultivate tumor material in 3D cell cultures in order to test which drug combinations are the most likely to be successful in which molecular profile. The results are part of a comprehensive diagnosis, from which an interdisciplinary team of experts will in the molecular tumor conference derive a therapy recommendation. "This also enables physicians to select specific patients for clinical studies on new drugs, because they are the most likely to benefit from the respective treatments" explains Keilholz. "The decision in favor of the cooperation project is an important step in pooling the clinical expertise as well as the expertise of the Charité and industry in the field of personalized precision medicine."

Patient-specific 3D cell cultures and mouse lines are already used in basic research and in drug development. So far, individual test systems have only been available for selected patients and for specific cancers. In cooperation with the biotech companies, the pool of pre-clinical test systems will now be extended systematically to cover various cancer types. "The EFRE funding represents a decisive impulse for the biotech landscape and the health industry in the region" Professor Axel Radlach Pries, Dean of the Carité points out.

An image for this press release is available for download at
www.dkfz.de/de/presse/pressemitteilungen/2016/bilder/GM130-G12_Regan.jpg

Legend: Colon cancer cells growing into a 3-dimensional organoid cell culture in a culture dish.

Note on use of images related to press releases

Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: "Source: Dr. Joseph Regan"
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ's Press Office (phone: ++49-(0)6221 42 2854, E-mail: presse@dkfz.de). Any commercial use is prohibited.

The German Cancer Consortium (DKTK) is a joint long-term initiative involving the German Federal Ministry of Education and Research (BMBF), participating German states and the German Cancer Research Center (DKFZ) and was established as one of six German Health Research Centres (DZGs). As DKTK's core center the DKFZ works together with research institutions and hospitals in Berlin, Dresden, Essen/Düsseldorf, Frankfurt/Mainz, Freiburg, Munich, Heidelberg and Tübingen to create the best possible conditions for clinically oriented cancer research. The consortium promotes interdisciplinary research at the interface between basic research and clinical research, as well as clinical trials for innovative treatments and diagnostic methods. Another key focus of the consortium's work is on developing research platforms to speed up the application of personalized cancer treatments and to improve the diagnosis and prevention of cancer.

More information is available at http://www.dkfz.de/de/dktk/

Press contact:

Dr. Stefanie Seltmann
Head of Press and Public Relations
German Cancer Research Center
Im Neuenheimer Feld 280
D-69120 Heidelberg
T: +49 6221 42 2854
F: +49 6221 42 2968
presse@dkfz.de
www.dkfz.de

Dr. Alexandra Moosmann
German Cancer Research Center
Press and Public Relations
German Cancer Consortium
Im Neuenheimer Feld 280
69120 Heidelberg
Phone: +49 6221 42 1662
Email: a.moosmann@dkfz-heidelberg.de
www.dkfz.de/en/dktk

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS